Organon Co Stock Today
| OGN Stock | USD 20.29 0.13 0.64% |
Performance1 of 100
| Odds Of DistressLess than 9
|
Organon is selling at 20.29 as of the 13th of September 2024; that is 0.64% increase since the beginning of the trading day. The stock's open price was 20.16. Organon has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Note, on June 15, 2021, Representative Scott Franklin of US Congress acquired under $15k worth of Organon's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of June 2021 | Category Healthcare | Classification Health Care |
Organon Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Organon Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon CO operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. The company has 257.47 M outstanding shares of which 7.8 M shares are now shorted by investors with about 3.95 days to cover. More on Organon Co
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Organon Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, SP Small-Cap 600, ARCA Pharmaceutical, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsOrganon can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Organon's financial leverage. It provides some insight into what part of Organon's total assets is financed by creditors.
| |||||
Organon Co (OGN) is traded on New York Stock Exchange in USA. It is located in 30 Hudson Street, Jersey City, NJ, United States, 07302 and employs 10,000 people. Organon is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 5.19 B. Organon runs under Pharmaceuticals sector within Health Care industry. The entity has 257.47 M outstanding shares of which 7.8 M shares are now shorted by investors with about 3.95 days to cover.
Organon Co has about 706 M in cash with 799 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.14.
Check Organon Probability Of Bankruptcy
Ownership AllocationOrganon owns a total of 257.47 Million outstanding shares. The majority of Organon Co outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Organon to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Organon. Please pay attention to any change in the institutional holdings of Organon as this could imply that something significant has changed or is about to change at the company. Please note that on June 15, 2021, Representative Scott Franklin of US Congress acquired under $15k worth of Organon's common stock.
Check Organon Ownership Details
Organon Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Aqr Capital Management Llc | 2024-06-30 | 3.5 M | |
| Deprince Race & Zollo Inc | 2024-06-30 | 3.4 M | |
| Fmr Inc | 2024-06-30 | 2.8 M | |
| Principal Financial Group Inc | 2024-06-30 | 2.7 M | |
| Charles Schwab Investment Management Inc | 2024-06-30 | 2.4 M | |
| Dimensional Fund Advisors, Inc. | 2024-06-30 | 2.4 M | |
| Amvescap Plc. | 2024-06-30 | 2.2 M | |
| Thompson, Siegel & Walmsley Llc | 2024-06-30 | 2.1 M | |
| Private Management Group Inc | 2024-06-30 | 1.9 M | |
| Blackrock Inc | 2024-06-30 | 32.6 M | |
| Vanguard Group Inc | 2024-06-30 | 30.2 M |
Organon Historical Income Statement
Organon Stock Against Markets
Organon Corporate Management
| Susan ONeal | Chief Officer | Profile | |
| Rebecca Edwards | Chief Officer | Profile | |
| Rachel Stahler | Executive Officer | Profile | |
| Susanne Fiedler | Executive Officer | Profile | |
| Daniel Karp | Chief Officer | Profile | |
| Aaron Falcione | Executive Officer | Profile |
Additional Information and Resources on Investing in Organon Stock
When determining whether Organon offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Organon's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Organon Co Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Organon Co Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organon Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organon. If investors know Organon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.21) | Dividend Share 1.12 | Earnings Share 3.88 | Revenue Per Share 24.784 | Quarterly Revenue Growth (0) |
The market value of Organon is measured differently than its book value, which is the value of Organon that is recorded on the company's balance sheet. Investors also form their own opinion of Organon's value that differs from its market value or its book value, called intrinsic value, which is Organon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organon's market value can be influenced by many factors that don't directly affect Organon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Organon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.